Alnylam Assist® Case Manager Support

Alnylam Assist® Can Support Your Patients

Alnylam Assist® offers personalized, comprehensive support for your patients throughout treatment with  GIVLAARI® (givosiran)

Our dedicated Case Managers are here to help your patients.

Call Us:

1-833-256-2748

Monday - Friday, 8am - 6pm ET

Enroll Your Patients

How Alnylam Assist® Can Help

Alnylam Assist® offers a wide range of services to guide your patients throughout treatment with GIVLAARI.

Alnylam Assist® - Understanding Insurance Benefits

Benefit Verification

Help determining patient-specific coverage

Alnylam Assist® - Financial Assistance

Financial Assistance

Information about patient eligibility for financial assistance

Alnylam Assist® - Patient Education

Patient Education

Disease and product education for patients and families

Alnylam Assist® - Reimbursement Support

Reimbursement Support

Education on the prior authorizations, claims, and appeals processes

Forms and Documents

Download the materials below for more information about Alnylam Assist®

See All Forms and Documents ›

Alnylam Assist® - Downloadable PDF

Alnylam Assist® Services
Overview Brochure

Download

Alnylam Assist® - Downloadable PDF

Alnylam Assist® Brochure
for Patients

Download

Enroll Your Patients

Begin the conversation with our team and help your adult patients with acute hepatic porphyria join Alnylam Assist® today.

1-833-256-2748

Monday - Friday, 8am - 6pm ET

Enroll Your Patients

Enroll Your Patients Now

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›

or

Alnylam Assist® Start Form - To Print And Fax

Print
& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP Triangles

IMPORTANT SAFETY INFORMATION

Contraindications

GIVLAARI® (givosiran) is contraindicated in patients with known severe hypersensitivity to givosiran. Reactions have included anaphylaxis.

Anaphylactic Reaction

Anaphylaxis has occurred with GIVLAARI treatment (<1% of patients in clinical trials). Ensure that medical support is available to appropriately manage anaphylactic reactions when administering GIVLAARI. Monitor for signs and symptoms of anaphylaxis. If anaphylaxis occurs, immediately discontinue administration of GIVLAARI and institute appropriate medical treatment.

Hepatic Toxicity

Transaminase elevations (ALT) of at least 3 times the upper limit of normal (ULN) were observed in 15% of patients receiving GIVLAARI in the placebo-controlled trial. Transaminase elevations primarily occurred between 3 to 5 months following initiation of treatment.

Measure liver function tests prior to initiating treatment with GIVLAARI, repeat every month during the first 6 months of treatment, and as clinically indicated thereafter. Interrupt or discontinue treatment with GIVLAARI for severe or clinically significant transaminase elevations. In patients who have dose interruption and subsequent improvement, reduce the dose to 1.25 mg/kg once monthly. The dose may be increased to the recommended dose of 2.5 mg/kg once monthly if there is no recurrence of severe or clinically significant transaminase elevations at the 1.25 mg/kg dose.

Renal Toxicity

Increases in serum creatinine levels and decreases in estimated glomerular filtration rate (eGFR) have been reported during treatment with GIVLAARI. In the placebo-controlled study, 15% of patients receiving GIVLAARI experienced a renally-related adverse reaction. The median increase in creatinine at Month 3 was 0.07 mg/dL. Monitor renal function during treatment with GIVLAARI as clinically indicated.

Injection Site Reactions

Injection site reactions were reported in 25% of patients receiving GIVLAARI in the placebo-controlled trial. Symptoms included erythema, pain, pruritus, rash, discoloration, or swelling around the injection site. One (2%) patient experienced a single, transient, recall reaction of erythema at a prior injection site with a subsequent dose administration.

Drug Interactions

Concomitant use of GIVLAARI increases the concentration of CYP1A2 or CYP2D6 substrates, which may increase adverse reactions of these substrates. Avoid concomitant use of GIVLAARI with CYP1A2 or CYP2D6 substrates for which minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP1A2 or CYP2D6 substrate dosage in accordance with approved product labeling.

Adverse Reactions

The most common adverse reactions that occurred in patients receiving GIVLAARI were nausea (27%) and injection site reactions (25%).

INDICATION

GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).

For additional information about GIVLAARI, please see full Prescribing Information.